CGC729
Relapsed/Refractory Metastatic Clear Cell Renal Cell Carcinoma
Phase 1Active
Key Facts
Indication
Relapsed/Refractory Metastatic Clear Cell Renal Cell Carcinoma
Phase
Phase 1
Status
Active
Company
About CureGenetics
A clinical-stage biotech developing novel CAR-NKT and AAV gene therapies for solid tumors and genetic diseases.
View full company profile